← Every company
Novavax Inc Patents
What Novavax Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
NVAX on carbonthat →Filings on file
43
Granted
0
Still pending
43
Filed under
4 names
43 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| PROTEIN-BASED DRUG PRODUCTS USING MONOESTER-FREE POLYSORBATE DETERGENTA61K 9/5123, A61K 9/5192, A61K 39/00, A61K 39/12, A61K 39/215, A61K 39/385, A61K 39/39, A61K2039/55505, A61K2039/55555, A61K2039/55566Filed as NOVAVAX, INC.2026-03-27Marco CACCIUTTOLO | pending |
| HEMAGGLUTINATION INHIBITION ASSAYS FOR THE EVALUATION OF SEASONAL INFLUENZA VACCINESG01N 33/56983, G01N2333/11, G01N2469/20, G01N2500/04Filed as NOVAVAX, INC.2026-02-09Raj KALKERI | pending |
| ASSAYS FOR THE EVALUATION OF SEASONAL COVID-INFLUENZA COMBINATION VACCINESG01N 33/5023, G01N 33/56983, G01N 33/502, G01N 33/5047, G01N2333/11, G01N2333/15, G01N2333/165, G01N2333/948, G01N2469/20, G01N2800/52Filed as NOVAVAX, INC.2026-02-09Raj KALKERI | pending |
| ANTI-SARS-COV-2 SPIKE (S) IMMUNOASSAY AND METHODS OF USE THEREOFG01N 33/56983, G01N 33/6854, C07K 14/005, C12N2770/20022, C12Q 1/28, G01N2333/165, G01N2333/908, G01N2469/20Filed as NOVAVAX, INC.2026-01-14Mingzhu ZHU | pending |
| RIBONUCLEIC ACID COMPOSITIONS HAVING ENHANCED IMMUNOGENICITYA61K 39/12, A61K 39/215, A61P 37/04, A61K 39/145, A61K 39/39, A61K2039/53, A61K2039/55555, A61K2039/55577, A61K2039/70, C12N2760/16134, C12N2770/20034Filed as NOVAVAX, INC.2026-01-12Gale SMITH | pending |
| RIBONUCLEIC ACID COMPOSITIONS HAVING ENHANCED IMMUNOGENICITYFiled as NOVAVAX, INC.2026-01-12GALE SMITH | pending |
| IMMUNOGENIC VARICELLA ZOSTER VACCINE COMPOSITIONSA61K 39/12, A61K 39/25, A61P 31/22, A61P 37/04, A61K2039/545, A61K2039/55555, A61K2039/55572, A61K2039/55577, A61K2039/575, C12N2710/16734Filed as NOVAVAX, INC.2026-01-09Gale SMITH | pending |
| CORONAVIRUS VACCINE FORMULATIONSA61P 31/14, A61K 39/215, A61K 39/12, A61K2039/545, A61K2039/55555, A61K2039/55577, C12N2770/20034Filed as Novavax, Inc.2025-10-24Gale SMITH | pending |
| PNEUMOCOCCAL CONJUGATE VACCINES WITH SAPONIN-BASED ADJUVANTSA61K 39/092, A61P 31/04, A61K2039/545, A61K2039/55505, A61K2039/55555, A61K2039/55577, A61K2039/55583, A61K2039/60, A61K2039/6037, A61K2039/70Filed as NOVAVAX, INC.2025-08-07Nita PATEL | pending |
| RSV F VACCINE FORMULATIONSFiled as NOVAVAX, INC.2025-08-02Nita PATEL | pending |
| METHODS OF QUANTIFYING SAPONINS PRESENT IN PARTICLES COMPRISING SAPONIN AND LIPIDG01N 24/08, G01R 33/4625Filed as NOVAVAX, INC.2025-07-18Torgny RUNDLÖF | pending |
| PROTEIN-BASED DRUG PRODUCTS USING MONOESTER-FREE POLYSORBATE DETERGENTFiled as NOVAVAX, INC.2025-03-28Marco CACCIUTTOLO | pending |
| AVIAN INFLUENZA NANOPARTICLE IMMUNOGENIC COMPOSITIONSA61K 39/12, A61K 39/145, A61P 37/04, A61K2039/54, A61K2039/543, A61K2039/55555, C12N2760/16134Filed as Novavax, Inc.2025-03-04Gale SMITH | pending |
| AVIAN INFLUENZA NANOPARTICLE IMMUNOGENIC COMPOSITIONSFiled as NOVAVAX, INC.2025-03-04GALE SMITH | pending |
| ASSAYS FOR THE EVALUATION OF SEASONAL COVID-INFLUENZA COMBINATION VACCINESFiled as Novavax, Inc.2025-02-07Raj KALKERI | pending |
| HEMAGGLUTINATION INHIBITION ASSAYS FOR THE EVALUATION OF SEASONAL INFLUENZA VACCINESFiled as Novavax, Inc.2025-02-07Raj KALKERI | pending |
| ACE2 INHIBITION ASSAY FOR EVALUATION OF VACCINE IMMUNOGENICITYC07K 14/005, G01N 33/56983, G01N 33/6803, C12N2770/20022, G01N2333/165, G01N2333/948, G01N2469/20Filed as NOVAVAX, INC.2025-01-25Joyce S. PLESTED | pending |
| PSEUDOVIRUS BASED NEUTRALIZATION ASSAY FOR EVALUATING VACCINE IMMUNOGENICITYC12N 15/86, C12Q 1/70, C07K 14/005, C12N 7/00, C12N2740/00043, C12N2740/00051, C12N2740/16043, C12N2770/20022, C12Q 1/6897Filed as NOVAVAX, INC.2025-01-25Zhaohui CAI | pending |
| ANTI-SARS-COV-2 SPIKE (S) IMMUNOASSAY AND METHODS OF USE THEREOFFiled as Novavax, Inc.2025-01-14Mingzhu ZHU | pending |
| IMMUNOGENIC VARICELLA ZOSTER VACCINE COMPOSITIONSFiled as Novavax, Inc.2025-01-10Gale SMITH | pending |
| RIBONUCLEIC ACID VACCINE COMPOSITIONS HAVING ENHANCED IMMUNOGENICITYFiled as Novavax, Inc.2025-01-10Gale SMITH | pending |
| AVIAN INFLUENZA NANOPARTICLE IMMUNOGENIC COMPOSITIONSFiled as Novavax, Inc.2024-11-13Gale Smith | pending |
| INTRANASAL IMMUNOGENIC COMPOSITIONSA61K 39/215, A61P 31/14, A61K 9/0043, A61K 39/145, A61K 39/155, A61K 47/02, A61K 47/26, A61K2039/543, A61K2039/55577, A61K2039/575, A61K2039/70, C12N 7/00, C12N2760/16134, C12N2760/16234, C12N2760/18534, C12N2770/20034Filed as Novavax AB2024-11-06Gale SMITH | pending |
| INTRANASAL IMMUNOGENIC COMPOSITIONSFiled as NOVAVAX, INC.2024-11-06GALE SMITH | pending |
| COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST EPSTEIN-BARR VIRUSA61K 39/12, A61K2039/55577, A61K2039/6031, C07K 14/005, C07K 14/47, C07K2319/02, C07K2319/735, C12N2710/16222, C12N2710/16234Filed as NOVAVAX, INC.2024-09-30Gregory GLENN | pending |
| ANTI-SARS-COV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19Filed as NOVAVAX, INC.2024-09-28GALE SMITH | pending |
| ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19C07K 16/104, C07K2317/33, C07K2317/55, C07K2317/76, C07K2317/92, G01N 33/56983, G01N2333/165, G01N2469/10, G01N2469/20Filed as NOVAVAX, INC.2024-09-28Gale SMITH | pending |
| METHOD FOR DETECTING ANTI-SARS-COV-2 SPIKE (S) IMMUNOGLOBULINSFiled as NOVAVAX, INC.2024-09-11JOYCE S. PLESTED | pending |
| METHOD FOR DETECTING ANTI-SARS-COV-2 SPIKE (S) IMMUNOGLOBULINSG01N 33/56983, G01N 33/6854, G01N2333/165, G01N2469/20Filed as NOVAVAX, INC.2024-09-11Joyce S. PLESTED | pending |
| METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASEA61K 9/5115, A61K 9/5123, A61P 31/14, A61P 11/00, A61K 39/12, A61K 39/155, C12N2760/16022, C12N2760/16034, C12N2760/18522, C12N2760/18534Filed as NOVAVAX, INC.2024-09-09Gale SMITH | pending |
| MATRIX-M VACCINE FORMULATIONS OF PNEUMOCOCCAL CONJUGATESFiled as NOVAVAX, INC.2024-08-07Nita PATEL | pending |
| ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19C07K 16/104, A61P 31/14, A61K2039/505, C07K2317/33, C07K2317/34, C07K2317/565, C07K2317/76, C07K2317/92Filed as NOVAVAX, INC.2024-06-23Gale SMITH | pending |
| CORONAVIRUS VACCINE FORMULATIONSA61K 39/215, C07K 14/005, A61P 31/14, A61K 9/5123, A61K 39/12, A61K2039/5252, A61K2039/53, A61K2039/55555, A61K2039/55577, A61K2039/575, B82Y 5/00, C12N2770/20022, C12N2770/20023, C12N2770/20034, C12N2770/20071Filed as NOVAVAX, INC.2024-05-30Gale SMITH | pending |
| METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MALARIAA61K 39/015, C07K 14/445, A61P 33/06, Y02A 50/30, A61P 33/02, A61K2039/523, A61K2039/545, A61K2039/55555, A61K2039/55577Filed as NOVAVAX, INC.2024-05-21Jenny M. REIMER | pending |
| MALARIA VACCINE FORMULATIONSA61K 39/015, C07K 14/005, A61P 33/10, A61P 37/04, A61P 31/14, Y02A 50/30, A61K 39/12, A61K 39/292, A61K 39/39, A61K2039/545, A61K2039/55577, A61K2039/575, C07K 14/445, C07K2319/00, C12N2730/10122, C12N2730/10134, C12N2760/20134, A61P 33/06, A61K2039/6075Filed as NOVAVAX, INC.2024-04-25Jenny M. REIMER | pending |
| SARS-COV-2 VACCINE COMPOSITIONSA61K 39/215, C12N 7/00, A61P 31/14, A61K 39/12, A61K2039/53, A61K2039/54, A61K2039/545, A61K2039/55505, A61K2039/55555, A61K2039/55577, A61K2039/572, A61K2039/575, A61K2039/60, A61K2039/70, C07K 14/005, C12N2770/20022, C12N2770/20034Filed as Novavax, Inc.2024-04-24Gale SMITH | pending |
| SARS-COV-2 VACCINE COMPOSITIONSFiled as NOVAVAX, INC.2024-04-24GALE SMITH | pending |
| CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEMFiled as NOVAVAX, INC.2024-04-03NITA PATEL | pending |
| CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEMA61K 39/12, A61K 39/215, A61P 31/14, A61P 31/16, A61K 39/145, A61K2039/53, A61K2039/543, A61K2039/545, A61K2039/55555, A61K2039/55577, A61K2039/575, A61K2039/70, C12N2760/16134, C12N2760/16234, C12N2770/20022, C12N2770/20034Filed as Novavax, Inc.2024-04-03Nita PATEL | pending |
| INFLUENZA NANOPARTICLE IMMUNOGENIC COMPOSITIONSFiled as Novavax Inc.2024-03-04Gale Smith | pending |
| SAPONIN-BASED ADJUVANTS FOR VACCINESFiled as Novavax AB2024-03-01Anna-Karin Palm | pending |
| RSV F VACCINE FORMULATIONSFiled as NOVAVAX, INC.2024-02-05NITA PATEL | pending |
| MULTIVALENT INFLUENZA NANOPARTICLE VACCINESA61P 31/16, A61K 39/12, A61K 39/145, A61P 37/04, A61K 9/0051, A61K 9/51, A61K 39/295, A61K 39/39, A61K2039/5258, A61K2039/55555, A61K2039/55577, A61K2039/70, C12N2760/16134, C12N2760/16171, C12N2760/16234, C12N2760/16271Filed as Novavax, Inc.2024-01-03Sarathi BODDAPATI | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on NVAX
Company overviewEverything on NVAX in one place, with the price.SEC filingsWhat NVAX's 8-Ks say happened: results, departures, auditor changes.Executive payWhat NVAX awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in NVAX.Funds holding itWhich funds and ETFs hold NVAX, and how big a bet.LobbyingWhat NVAX spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on NVAX's account, and who they worked for.Federal contractsWhat federal agencies pay NVAX.